Branded

Leqembi is indicated for the treatment of Alzheimer’s disease.

Briumvi is used to treat relapsing forms of multiple sclerosis, including clinically isolated syndrome, relapsing-remitting disease and active secondary progressive disease, in adults.

Urovant Sciences and Holly Robinson Peete are bringing awareness to overactive bladder symptoms and management options as part of a new campaign.

Sunlenca is a new type of antiretroviral medication for adult patients living with HIV-1, whose HIV infections cannot be successfully treated with other available treatments due to resistance, intolerance or safety considerations.

Hemgenix is the first gene therapy to treat adults with Hemophilia B.

Sezaby is the first and only product approved for treating seizures in neonatal patients.

Tzield is the first and only treatment indicated to delay the onset of stage 3 type 1 diabetes in adult and pediatric patients aged 8 years old and older with stage 2 type 1 diabetes.

With this FDA approval, Liletta has one of the longest approved durations of use for a hormonal intrauterine device in the United States. 

The technology aims to help adults living with Type 1 or Type 2 diabetes and clinicians make informed, data-backed decisions.

Vemlidy is now approved for the treatment of chronic Hepatitis B virus infection in pediatric patients.

Lupin is acquiring Brovana inhalation solution and Xopenex HFA inhalation aerosol from Sunovion for $75 million.

Tecvayli, an off-the-shelf, subcutaneous therapy, is an important new medicine for patients with incurable blood cancer who face limited treatment options.